https://www.zacks.com/stock/news/2203479/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now?cid=CS-ZC-FT-smart_beta_etf-2203479
Dec 29, 2023 - Smart Beta ETF report for HDV
zc:1300492815081523510
0
https://www.zacks.com/commentary/2208227/top-analyst-reports-for-johnson-johnson-micron-technology-southern-company?cid=CS-ZC-FT-research_daily-2208227
Jan 10, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Micron Technology, Inc. (MU) and The Southern Company (SO).
zc:7337866903638540686
0
https://seekingalpha.com/news/4056938-jnj-looking-to-move-talc-powder-unit-to-texas-ahead-of-bankruptcy-filing-report?source=feed_sector_healthcare
Jan 22, 2024 - Johnson & Johnson (JNJ) is reportedly looking to relocate its LTL talc powder unit to Texas ahead of an expected third bankruptcy filing for the subsidiary. Read more here.
0
sa:-6988141442641183309
0
https://www.zacks.com/stock/news/2214282/johnson-johnson-jnj-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2214282
Jan 23, 2024 - The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zc:-5316539770897093449
0
https://www.fool.com/earnings/call-transcripts/2024/01/23/johnson-johnson-jnj-q4-2023-earnings-call-transcri/?source=iedfolrf0000001
Jan 23, 2024 - JNJ earnings call for the period ending December 31, 2023.
0
fool:-5756587576249076656
0
https://www.zacks.com/stock/news/2216453/key-takeaways-from-jnj-s-jnj-q4-earnings-presentation?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2216453
Jan 26, 2024 - J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.
zc:-1151424455399479259
0
https://www.zacks.com/stock/news/2220511/abbvie-abbv-q4-earnings-beat-raises-sales-view-for-key-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-2220511
Feb 02, 2024 - AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
zc:-2017038614076952031
0
https://www.fool.com/investing/2024/02/03/7-dividend-stocks-that-pay-me-more-than-500-per-mo/?source=iedfolrf0000001
Feb 03, 2024 - These stocks pay safe, reliable, and growing dividends.
0
fool:-8143902548400009636
0
https://www.zacks.com/commentary/2223994/top-research-reports-for-johnson-johnson-walt-disney-uber?cid=CS-ZC-FT-research_daily-2223994
Feb 09, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and Uber Technologies, Inc. (UBER).
zc:8028952784333983336
0
https://www.zacks.com/stock/news/2235489/j-j-jnj-secures-full-fda-nod-for-rybrevant-in-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2235489
Mar 04, 2024 - The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
zc:4163593556888934980
0